NCT00533169 - ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Neuroblastoma

Interventions

DRUG

ZD6474

Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.

DRUG

Retinoic Acid

Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).

Trial Locations (1)

U.T.M.D. Anderson Cancer Center, Houston